Trends in antibiotic susceptibility of bloodstream pathogens in hospitalized patients in France, 1996 to 2007

Diagnostic Microbiology and Infectious Disease

Volumn 66, Issue 3, 2010, Pages 292-300

  Decousser, Jean Winoc ^a   Lamy, Brigitte ^b   Pina, Patrick ^c   Allouch, Pierre Yves ^d  

^a HÔPITAL ANTOINE BÉCLÈRE   (France)

^b Centre Hospitalier du Bassin de Thau   (France)

^c Hôpital de Plaisir Grignon   (France)

^d CENTRE HOSPITALIER DE VERSAILLES   (France)

Author keywords

Antimicrobial susceptibility; Bloodstream infection; France; Trends

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; CEFOTAXIME; GENTAMICIN; NALIDIXIC ACID; OXACILLIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TEICOPLANIN; VANCOMYCIN;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; BACTERIUM ISOLATION; BLOODSTREAM INFECTION; DISEASE SEVERITY; ENTEROBACTERIACEAE; ESCHERICHIA COLI; FRANCE; HEALTH SURVEY; HOSPITAL PATIENT; HUMAN; NONHUMAN; PRIORITY JOURNAL; QUALITY CONTROL; STAPHYLOCOCCUS AUREUS;

ANTI-BACTERIAL AGENTS; BACTEREMIA; CHI-SQUARE DISTRIBUTION; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTIONS; FRANCE; HUMANS; MICROBIAL SENSITIVITY TESTS; POPULATION SURVEILLANCE; PROSPECTIVE STUDIES; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS;

EID: 77349099254     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2009.10.007     Document Type: Article

References (34)

1. Bax R., Bywater R., Cornaglia G., Goosens H., Hunter P., Isham V., Jarlier V., Jones R., Phillips I., Sahm D., Senn S., Struelens M., White A. Surveillance of antimicrobial resistance-what, how and whither?. Clin. Microbiol. Infect. 2001, 7:316-325.
2. Biedenbach D.J., Moet G.J., Jones R.N. Occurrence and antimicrobial resistance pattern comparisons among bloodstream infection isolates from the SENTRY Antimicrobial Surveillance Program (1997-2002). Diagn. Microbiol. Infect. Dis. 2004, 50:59-69.
3. Cornaglia G., Hryniewicz W., Jarlier V., Kahlmeter G., Mittermayer H., Stratchounski L., Baquero F. European recommendations for antimicrobial resistance surveillance. Clin. Microbiol. Infect. 2004, 10:349-383. on behalf of the ESCMID Study Group for Antimicrobial Resistance, sistance Surveillance (ESGARS)sistance Surveillance (ESGARS).
4. Dalgaard P. Tabular data; k proportions, test for trend (chapter 7.3). Introductory statistics with R 2002, 133-134. Springer-Verlaag, New York. J. R. Chambers, S. Sheater, W. Eddy, L. Tierney, W. Härdle (Eds.).
5. Dalgaard P. ANOVA and Kruskal-Wallis. Introductory statistics with R 2002, 112-127. Springer-Verlaag, New York. J. R. Chambers, S. Sheater, W. Eddy, L. Tierney, W. Härdle (Eds.).
6. Decousser J.W., Pina P., Picot F., Delalande C., Pangon B., Courvalin P., Allouch P.Y. Frequency of isolation and antimicrobial susceptibility of bacterial pathogens isolated from patients with bloodstream infections: a French prospective national survey. J. Antimicrob. Chemother. 2003, 51:1213-1222. the ColBVH study group.
7. Decousser J.W., Pina P., Viguier F., Picot F., Courvalin P., Allouch P.Y. Invasive Streptococcus pneumoniae in France: antimicrobial resistance, serotype, and molecular epidemiology findings from a monthly national study in 2000 to 2002. Antimicrob. Agents Chemother. 2004, 48:3636-3639. the ColBVH study group.
8. EARSS Annual report 2007 (27 November 2008, date last accessed). http://www.rivm.nl/earss/Images/EARSS%202007_FINAL_tcm61-55933.pdf.
9. Erb A., Stürmer T., Marre R., Brenner H. Prevalence of antibiotic resistance in Escherichia coli: overview of geographical, temporal, and methodological variations. Eur. J. Clin. Microbiol. Infect. Dis. 2007, 26:83-90.
10. Fridkin S.K., Hill H.A., Volkova N.V., Edwards J.R., Lawton R.M., Gaynes R.P., McGowan J.E. Temporal changes in prevalence of antimicrobial resistance in 23 U.S. Hospitals. Emerg. Infect. Dis. 2002, 8:697-701. the Intensive Care Antimicrobial Resistance Epidemiology (ICARE) Project Hospital.
11. Galas M., Decousser J.W., Breton N., Godard T., Allouch P.Y., Pina P. Nationwide study of the prevalence, characteristics, and molecular epidemiology of extended-spectrum β-lactamase producing Enterobacteriaceae in France. Antimicrob. Agents Chemother. 2008, 52:786-789. the ColBVH study group.
12. Guidelines of the Antimicrobial Committee of the French Society of Microbiology (27 November 2008, date last accessed). http://www.sfm.asso.fr/nouv/general.php?pa=2.
13. Guidelines of the Antimicrobial Committee of the French Society of Microbiology (27 November 2008, date last accessed). http://www.sfm.asso.fr/publi/general.php?pa=5.
14. Guidelines of the National Observatory of the Bacterial Resistance Epidemiology, ONERBA (27 November 2008, date last accessed). http://www.onerba.org/rubrique.php3?id_rubrique=15.
15. Heyn B., Le Moal M., Armand-Lefevre L., Nicolas-Chanoine M.H. Multilocus sequence typing (MLST) shows that the "Iberian" clone of oxacillin-resistant Staphylococcus aureus has spread to France and acquired reduced susceptibility to teicoplanin. J. Antimicrob. Chemother. 2002, 50:323-329.
16. Horan T.C., Andrus M., Dudeck M.A. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am. J. Infect. Control. 2008, 36:309-332.
17. Jarlier V., Nicolas M., Fournier G., Philippon A. Extended broad-spectrum β-lactamases conferring transferable resistance to newer β-lactam agents in Enterobacteriaceae: hospital prevalence and susceptibility patterns. Rev. Infect. Dis. 1988, 10:867-878.
18. Karlowsky J.A., Jones M.E., Draghi D.C., Thornsberry C., Sahm D.F., Volturo G.A. Prevalence and antimicrobial susceptibilities of bacteria isolated from blood cultures of hospitalized patients in the United States in 2002. Ann. Clin. Microbiol. Antimicrobiol. 2004, 10:3-7.
19. Laurent F., Lelièvre H., Cornu M., Vandenesch F., Carret G., Etienne J., Flandrois J.P. Fitness and competitive growth advantage of new gentamicin-susceptible MRSA clones spreading in French hospitals. J. Antimicrob. Chemother. 2001, 47:277-283.
20. Leibovici L., Vidal L., Paul M. Aminoglycoside drugs in clinical practice: an evidence-based approach. J. Antimicrob. Chemother. 2009, 63:246-251.
21. Livermore D.M., James D., Reacher M., Graham C., Nichols T., Stephens P., Johnson A.P., George R.C. Trends in fluoroquinolone (ciprofloxacin) resistance in Enterobacteriaceae from bacteremias, England and Wales, 1990-1999. Emerg. Infect. Dis. 2002, 8:473-478.
22. McGregor J.C., Rich S.E., Harris A.D., Prerencevich E.N., Osih R., Lodise T.P., Miller R.R., Furuno J.P. A systematic review of the methods used to assess the association between appropriate antibiotic therapy and mortality in bacteremic patients. Clin. Inf. Dis. 2007, 45:329-337.
23. Peralta G., Sanchez M.B., Garrido J.C., Benito D., Cano M.E., Martinez-Martinez L., Roiz P. Impact of antibiotic resistance and of adequate empirical antibiotic treatment in the prognosis of patients with Escherichia coli bacteremia. J. Antimicrob. Chemother. 2007, 60:855-863.
24. Poirel L., Nordmann P. Emergence of plasmid-mediated resistance to fluoroquinolones in Enterobacteriaceae. J. Antimicrob. Chemother. 2005, 56:463-469.
25. Reimer L.G., Wilson M.L., Weinstein M.P. Update on detection of bacteremia and fungemia. Clin. Microbiol. Rev. 1997, 10:444-465.
26. Robert J., Cambau E., Grenet K., Trystram D., Pean Y., Fievet M.H., Jarlier V. Trends in quinolone susceptibility of Enterobacteriaceae among inpatients of a large university hospital: 1992-98. Clin. Microbiol. Infect. 2001, 7:553-561.
27. Robert J., Bismuth R., Jarlier V. Decreased susceptibility to glycopeptides in methicillin-resistant Staphylococcus aureus: a 20 year study in a large French teaching hospital, 1983-2002. J. Antimicrob. Chemother. 2006, 57:506-510.
28. Robicsek A., Jacoby G.A., Hooper D.C. The worldwide emergence of plasmid-mediated quinolone resistance. Lancet Inf. Dis. 2006, 6:629-640.
29. Scarsi K.K., Feinglass J.M., Scheetz M.H., Postelnick M.J., Bolon M.K., Noskin G.A. Impact of inactive empiric antimicrobial therapy on inpatient mortality and length of stay. Antmicrob. Agents Chemother. 2006, 50:3355-3360.
30. Schwaber M.J., De-Medina T., Carmeli Y. Epidemiological interpretation of antibiotic resistance studies-what are we missing?. Nat. Rev. Microbiol. 2004, 2:979-983.
31. Shurland S., Zhan M., Bradham B.D., Roghmann M.C. Comparison of mortality risk associated with bacteremia due to oxacillin-resistant and oxacillin-susceptible Staphylococcus aureus. Infect. Control Hosp. Epidemiol. 2007, 28:273-279.
32. Swenson J.M., Lonsway D., McAllister S., Thompson A., Jevitt L., Zhu W., Patel J.B. Detection of mecA-mediated resistance using reference and commercial testing methods in a collection of Staphylococcus aureus expressing borderline oxacillin MICs. Diagn. Microbiol. Inf. Dis. 2007, 58:29-33.
33. Weinstein M.P., Towns M.L., Quartey S.M., Mirrett S., Reimer L.G., Parmigiani G., Reller L.B. The clinical significance of positive blood cultures in the 1990s: a prospective comprehensive evaluation of the microbiology, epidemiology, and outcome of bacteremia and fungemia in adults. Clin. Infect. Dis. 1997, 24:584-602.
34. Woodford N. Successful, multiresistant bacterial clones. J. Antimicrob. Chemother. 2008, 61:233-234.